Filter your results
- 3
- 1
- 4
- 4
- 1
- 2
- 1
- 4
- 3
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trialThe Lancet Respiratory Medicine, 2019, 7 (1), pp.46-59. ⟨10.1016/S2213-2600(18)30406-5⟩
Journal articles
hal-02052347v1
|
|||
|
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe AsthmaNew England Journal of Medicine, 2017, 376 (25), pp.2448--2458. ⟨10.1056/NEJMoa1703501⟩
Journal articles
hal-01761510v1
|
||
|
Defining a Severe Asthma Super-Responder: Findings from a Delphi ProcessJournal of Allergy and Clinical Immunology: In Practice, 2021, 9 (11), pp.3997-4004. ⟨10.1016/j.jaip.2021.06.041⟩
Journal articles
hal-03314809v1
|
||
|
Extracellular DNA, Neutrophil Extracellular Traps, and Inflammasome Activation in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2019, 199 (9), pp.1076-1085. ⟨10.1164/rccm.201810-1869OC⟩
Journal articles
hal-02997946v1
|